Roche Launches New VENTANA HER2 Dual ISH Companion Diagnostic Test to Advance Personalized Medicine in Breast and Gastric Cancers
Apr 24, 2019 07:52
CST Updated
07:52
Roche
Oncology Drug Research, Development, and Manufacturing
April 24, 2019 News /BioonBIOON/ --TumorPharmaceutical giant Roche recently announced the launch of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for detectionBreast Cancerand the HER2 biomarker in gastric cancer. HER2 (human epidermal growth factor receptor 2) is an importantBiomarkers, and their detection and inhibition help to treat these aggressive cancers more effectively. Globally, each yearDiagnosisThere are nearly 2.1 million new cases of breast cancer, with over 620,000 deaths expected from the disease; approximately 15–20% of breast cancer patients are HER2-positive.
This is a new VENTANA HER2 dual in situ hybridization companionDiagnosisThis kit, designed for breast and gastric cancer patients eligible for targeted therapy, enables same-day completion, allowing clinicians to obtain results faster than with the most common HER2 confirmation methods. Furthermore, the results can be read using a standard light microscope, eliminating the need for specialized fluorescence microscopy.
Michael Heuer, CEO of Roche Diagnostics, stated, “This new VENTANA HER2 dual in situ hybridization companionDiagnosis"The kit will advance Roche's commitment to personalized medicine by delivering key information for treatment decisions more rapidly to patients with breast and gastric cancers. Rapid access to results is critical in the fight against cancer, where every second counts, and each day that clinicians and patients must wait for test results feels far too long."
Currently, this companionDiagnosisThe test kit is being launched in Europe, the Middle East, Africa, Latin America, and the Asia-Pacific region. Roche will also submit it to the U.S.FDAApproval.
Roche is the only supplier offering a fully automated brightfield dual in situ hybridization (ISH) solution for HER2 amplification testing. With the launch of the new VENTANA HER2 Dual ISH DNA Probe Cocktail Assay, Roche provides an improved brightfield analysis that runs with full automation on the BenchMark IHC/ISH instruments. This assay delivers definitive results more rapidly to pathology laboratories, enabling clinicians to make treatment decisions earlier.
As a global leader in the field of breast cancer diagnosis, Roche providesDiagnosisA comprehensive product with predictive analytics, including the VENTANA HER2/neu (4B5) rabbit monoclonal primary antibody, which helps assess breast cancer patients being considered for Herceptin therapy. (Bioon.com)